Paper Details
- Home
- Paper Details
Early termination of a trial of mycophenolate mofetil for treatment of interstitial cystitis/painful bladder syndrome: lessons learned.
Author: , BurksDavid A, CenLiyi, ChaiToby C, FitzGeraldMary P, FosterHarris E, HannoPhilip M, KrederKarl J, KusekJohn W, LandisJ Richard, LukaczEmily S, MayerRobert D, NickelJ Curtis, NybergLeroy M, PayneChristopher K, PetersKenneth M, PropertKathleen J, YangClaire C
Original Abstract of the Article :
PURPOSE: We evaluated the efficacy and tolerability of mycophenolate mofetil in patients with treatment refractory interstitial cystitis/painful bladder syndrome. MATERIALS AND METHODS: A total of 210 patients with interstitial cystitis/painful bladder syndrome were to be randomized into a multicen...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元:
https://pubmed.ncbi.nlm.nih.gov/21238993
データ提供:米国国立医学図書館(NLM)
Mycophenolate Mofetil for Treatment of Interstitial Cystitis/Painful Bladder Syndrome: A Study Halted
This research examines the efficacy and tolerability of [mycophenolate mofetil] in treating [interstitial cystitis/painful bladder syndrome (IC/PBS)], a chronic and often debilitating condition. It's like embarking on a caravan journey through the desert of IC/PBS research, seeking a cure for this elusive and painful condition. However, this journey was cut short when a safety warning was issued about the medication. This research highlights the complexities of clinical trials and the importance of safety in drug development.The Challenges of Drug Development and Safety
This research highlights the challenges of drug development and the importance of safety in clinical trials. The study was prematurely halted due to a safety warning about [mycophenolate mofetil], underscoring the need for ongoing vigilance and careful monitoring of new medications. It's a reminder that the desert of medical research is a challenging landscape, where unexpected obstacles can arise.Navigating the Uncertainties of IC/PBS Treatment
This research underscores the ongoing search for effective and safe treatments for [IC/PBS]. While [mycophenolate mofetil] showed promise in early trials, safety concerns led to the study's termination. It's a reminder that the journey towards a cure for IC/PBS is an ongoing one, with many challenges and uncertainties along the way.Dr.Camel's Conclusion
This study is a reminder that the search for effective treatments for challenging conditions like IC/PBS is a complex and often unpredictable journey. Safety must always be a top priority in drug development, and researchers must be prepared to adapt and adjust their strategies as new information emerges. It's a reminder that the desert of medical research is a dynamic landscape, with many twists and turns along the way.Date :
- Date Completed 2011-03-30
- Date Revised 2021-10-20
Further Info :
Related Literature
Article Analysis
SNS
PICO Info
in preparation
Languages
English
Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.